Cross-sectional study into quality of life issues surrounding insulin pump use in type 1 diabetes

TY - JOUR

T1 - Cross-sectional study into quality of life issues surrounding insulin pump use in type 1 diabetes

AU - Barnard, Katharine D.

AU - Skinner, T. Chas

PY - 2008/6/1

Y1 - 2008/6/1

N2 - This study aimed to determine whether continuous subcutaneous insulin infusion (CSII) is associated with improved quality of life (QoL) in routine care in the UK. We conducted a multiple cohort survey study of individuals with type 1 diabetes (matched for age, gender and frequency of blood glucose testing) using either CSII or multiple daily insulin injections (MDI). The World Health Organization QoL abbreviated questionnaire (WHOQOL-BREF), the Insulin Delivery System Rating Questionnaire (IDSRQ), the Problem Areas in Diabetes Scale (PAID), and the Hypoglycaemia Fear Scale (HFS) were used to assess QoL. In all, 642 people with type 1 diabetes returned questionnaires: 228 insulin pump users, 332 people using MDI and 82 using non-intensive insulin delivery. After controlling for confounding variables, CSII users reported that their treatment is more helpful (IDSRQ F=38.41, p<0.001), that it generates less worry (IDSRQ F=6.26, p<0.05), and that they are less likely to use hypoglycaemia avoidance behaviours (HFS F=467, p<0.05) and have fewer food-related problems (PAID p<0.01). In conclusion, even after controlling for self-care motivation, duration of current therapy and socio-economic environment, individuals using CSII reported better QoL than a matched cohort of individuals managing their diabetes using MDI.

AB - This study aimed to determine whether continuous subcutaneous insulin infusion (CSII) is associated with improved quality of life (QoL) in routine care in the UK. We conducted a multiple cohort survey study of individuals with type 1 diabetes (matched for age, gender and frequency of blood glucose testing) using either CSII or multiple daily insulin injections (MDI). The World Health Organization QoL abbreviated questionnaire (WHOQOL-BREF), the Insulin Delivery System Rating Questionnaire (IDSRQ), the Problem Areas in Diabetes Scale (PAID), and the Hypoglycaemia Fear Scale (HFS) were used to assess QoL. In all, 642 people with type 1 diabetes returned questionnaires: 228 insulin pump users, 332 people using MDI and 82 using non-intensive insulin delivery. After controlling for confounding variables, CSII users reported that their treatment is more helpful (IDSRQ F=38.41, p<0.001), that it generates less worry (IDSRQ F=6.26, p<0.05), and that they are less likely to use hypoglycaemia avoidance behaviours (HFS F=467, p<0.05) and have fewer food-related problems (PAID p<0.01). In conclusion, even after controlling for self-care motivation, duration of current therapy and socio-economic environment, individuals using CSII reported better QoL than a matched cohort of individuals managing their diabetes using MDI.

KW - CSH

KW - Health outcome

KW - Health status

KW - Insulin infusion

KW - Insulin pump

KW - QoL

KW - Weil-being

UR - http://www.scopus.com/inward/record.url?scp=54949103984&partnerID=8YFLogxK

U2 - 10.1002/pdi.1248

DO - 10.1002/pdi.1248

M3 - Journal article

AN - SCOPUS:54949103984

SN - 1357-8170

VL - 25

SP - 194

EP - 200

JO - Practical Diabetes International

JF - Practical Diabetes International

IS - 5

ER -